Neumora Therapeutics, Inc. (NASDAQ:NMRA) President Joshua Pinto Sells 8,048 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA) President Joshua Pinto sold 8,048 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $1.67, for a total transaction of $13,440.16. Following the sale, the president now owns 76,952 shares in the company, valued at approximately $128,509.84. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Neumora Therapeutics Stock Up 5.3 %

Shares of Neumora Therapeutics stock opened at $1.80 on Friday. The firm has a market cap of $290.81 million, a PE ratio of -0.96 and a beta of 2.50. Neumora Therapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $21.00. The company’s fifty day simple moving average is $4.30 and its two-hundred day simple moving average is $9.31.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Royal Bank of Canada cut shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price objective for the company from $29.00 to $4.00 in a research report on Thursday, January 2nd. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Bank of America decreased their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. William Blair reiterated an “outperform” rating on shares of Neumora Therapeutics in a research report on Wednesday, January 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.50.

Institutional Investors Weigh In On Neumora Therapeutics

Large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in Neumora Therapeutics in the 4th quarter worth $61,000. PNC Financial Services Group Inc. bought a new stake in Neumora Therapeutics in the 4th quarter worth $64,000. Quantbot Technologies LP bought a new stake in Neumora Therapeutics in the 4th quarter worth $92,000. PEAK6 LLC bought a new stake in Neumora Therapeutics in the 4th quarter worth $117,000. Finally, EntryPoint Capital LLC bought a new stake in Neumora Therapeutics in the 4th quarter worth $135,000. Institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.